Latest Breaking News On - Prz gastroenterol - Page 1 : comparemela.com

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® using PD-L1 IHC 22C3 pharmDx .

Nan Mburu: Support digestive health, weight loss, blood sugar, and hemorrhoids.

Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers

Amgen today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers . New data includes median overall survival a secondary endpoint that was reached with longer .

Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation

Amgen today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b overexpressing and human epidermal growth factor receptor 2 -negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with modified FOLFOX6 based on … – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (GEJ) adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin), based on an FDA-approved companion diagnostic assay showing at least 10% of tumor c

Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation